**Name of Journal:** *World Journal of Respirology*

**Manuscript NO:** 82961

**Manuscript Type:** CASE REPORT

**Pulmonary arterial hypertension confirmed by right heart catheterization following COVID-19 pneumonia: A case report and review of literature**

Henriques King M *et al*. Pulmonary arterial hypertension linked to COVID-19

Marshaleen Henriques King, Ifeoma Chiamaka Ogbuka, Vincent C Bond

**Marshaleen Henriques King,** Department of Pulmonary and Critical Care, Morehouse School of Medicine, Atlanta, GA 30310, United States

**Ifeoma Chiamaka Ogbuka,** Hospital Medicine, Covenant Health, Knoxville, TN 37922, United States

**Vincent C Bond,** Department of Microbiology, Biochemistry & Immunology, Morehouse School of Medicine, Atlanta, GA 30310, United States

**Author contributions:** Henriques King M, Ogbuka IC, and Bond VC contributed equally to this work; All authors have read and approve the final manuscript.

**Corresponding author: Ifeoma Chiamaka Ogbuka, MD, Doctor,** Hospital Medicine, Covenant Health, 244 Fort Saunders West Blvd, Knoxville, TN 37922, United States. icdwrites@gmail.com

**Received:** December 31, 2022

**Revised:** February 24, 2023

**Accepted:** May 8, 2023

**Published online:** May 26, 2023

**Abstract**

BACKGROUND

Pulmonary arterial hypertension (PAH) is a disease of the arterioles resulting in an increased resistance in pulmonary circulation with associated high pressures in the pulmonary arteries, causing irreversible remodeling of the pulmonary arterial walls. Coronavirus disease 2019 (COVID-19) has been associated with development of new onset PAH in the literature leading to symptoms of dyspnea, cough and fatigue that persist in spite of resolution of acute COVID-19 infection. However, the majority of these cases of COVID related PAH were diagnosed using echocardiographic data or *via* right heart catheterization in mechanically ventilated patients.

CASE SUMMARY

Our case is the first reported case of COVID related PAH diagnosed by right heart catheterization in a non-mechanically ventilated patient. Right heart catheterization has been the gold standard for diagnosis of pulmonary hypertension. Our patient had right heart catheterization four months after her initial COVID-19 infection due to persistent dyspnea.

CONCLUSION

This revealed new onset PAH that developed following her infection with COVID-19, an emerging sequela of the infection

**Key Words:** Pulmonary arterial hypertension post COVID-19 infection; PAH after COVID-19 infection; COVID-19 induced Pulmonary arterial hypertension diagnosed with right heart catheterization; Pulmonary arterial hypertension; Pulmonary arterial hypertension; Right heart catheterization; Right heart catheterization; COVID-19

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Henriques King M, Ogbuka IC, Bond VC. Pulmonary arterial hypertension confirmed by right heart catheterization following COVID-19 pneumonia: A case report and review of literature. *World J Respirol* 2023; 12(1): 10-15

**URL**: https://www.wjgnet.com/2218-6255/full/v12/i1/10.htm

**DOI**: https://dx.doi.org/10.5320/wjr.v12.i1.10

**Core Tip:** Pulmonary arterial hypertension has been reported in literature as a cardiovascular complication of coronavirus disease 2019 (COVID-19). To our knowledge, this is the first case report of pulmonary arterial hypertension confirmed by right heart catheterization in a non-ventilated patient following infection with COVID-19 complicated by hypoxic respiratory insufficiency.

**INTRODUCTION**

This case highlights pulmonary arterial hypertension (PAH) as a potential pulmonary-vascular complication of coronavirus disease 2019 (COVID-19).

**CASE PRESENTATION**

***Chief complaints***

A 71-year-old African American woman with a history of hypertension, chronic renal impairment and hyperlipidemia presented to the emergency department (ED) with fatigue, non-productive cough and mild dyspnea for a few days. She denied fever, myalgias, headaches, vomiting or diarrhea.

***History of present illness***

She worked at a medical facility and reported possible exposure to COVID-19 while at work.

***History of past illness***

She had no history of pulmonary disease, cardiac problems, venous thromboembolism, or sleep apnea. She denied smoking or use of illicit drugs.

***Personal and family history***

She also reported no family history of dyspnea.

***Physical examination***

On examination, her temperature was 98.4 F, pulse 73/min, blood pressure (BP) 118/74, respiratory rate 17/min and oxygen saturation 96% on room air. She had bibasilar crackles on chest auscultation with otherwise normal exam findings.

***Laboratory examinations***

Labs revealed a normal blood cell count, creatinine 2.08 mg/dL, N-terminal fragment of B-type natriuretic peptides 57 pg/mL, Troponin-T < 0.01 ng/mL and normal urinalysis.

***Imaging examinations***

Electrocardiographic showed normal sinus rhythm with no abnormalities. Her chest X-ray showed patchy opacities in the right lung with no pleural effusions.

**FINAL DIAGNOSIS**

She was COVID-19 tested, and initially discharged home on azithromycin with a subsequent positive test result two days later.

Seven days after her initial ED visit, she experienced worsening shortness of breath (SOB) and called 911. Emergency medical personnel, noting an oxygen saturation of 80%, placed her on supplemental oxygen at 2 L/min and transported her to the ED. There she reported severe SOB, a non-productive cough, loss of taste, and diarrhea. She denied fever, chest pain, or leg swelling.

Vitals revealed temperature 97.6 F, pulse 85/min, BP 94/71, respiratory rate 21/min with oxygen saturation 91% on 2 L/min *via* nasal cannula. On examination she had crackles bilaterally over the lung fields with an otherwise unremarkable exam.

Her labs revealed white blood cell count 9.47 × 109/L, creatinine 1.23 mg/dL, lactic acid 1.5 mmol/L, procalcitonin 0.13 ng/mL, C-reactive protein 8.4 mg/dL, D-dimer 521 ng/mL with D-Dimer 392 ng/mL, ferritin 1585 ng/mL. Repeat CXR found increased patchy opacities in both lungs. Renal impairment prevented use of chest computed tomography (CT) angiography to assess for an acute pulmonary embolism and a lung scan was not pursued given her lung opcacities which rendered that form of testing unreliable.

**TREATMENT**

She was admitted and placed on Levaquin for possible superimposed bacterial community-acquired pneumonia, vitamin C, and thiamine. Blood cultures showed no growth of any bacterial organisms, so antibiotics were discontinued. She improved clinically, was weaned off oxygen, and discharged home six days after admission.

**OUTCOME AND FOLLOW-UP**

Two weeks post-discharge, during out-patient follow-up with pulmonary medicine she reported persistence of fatigue, a predominantly nocturnal non-productive cough, and SOB episodes.

Pulmonary function test (PFT) revealed mild restrictive changes with no evidence of airway obstruction. The diffusing capacity was normal after adjusting for alveolar volume.

Transthoracic echocardiogram revealed normal left ventricular systolic function with mild diastolic dysfunction and normal left atrial pressure. Right ventricular systolic function was normal, but there was moderate tricuspid regurgitation and moderate pulmonary hypertension (PH), with an estimated right ventricular systolic pressure of 50 to 55 mmHg.

A six-minute walk test (6MWT) revealed no evidence of exercise desaturation on room air and she ambulated 708 feet during the test.

Right heart catheterization (RHC) was scheduled to further evaluate her PH, but was initially postponed due to a positive repeat COVID-19 test done prior to the procedure (2.5 mo after her initial COVID-19 diagnosis).

This was finally performed four months after initial COVID-19 positive test and revealed mild PAH Table 1.

A lung perfusion scan, to assess chronic thromboembolic pulmonary hypertension, revealed no evidence of acute or chronic pulmonary embolism. CT chest, to assess for interstitial pulmonary parenchymal abnormalities, showed clear lung fields with complete resolution of previous COVID-related lung opacities.

Patient was given the option to start Sildenafil however, given the fact that her pulmonary hypertension was mild at the time, the patient opted for watchful waiting and declined initiation of therapy. Patient was then referred to pulmonary rehabilitation following which her functional capacity improved slightly. She made the decision to retire early due to concerns of being re-exposed to COVID in the workplace.

**DISCUSSION**

COVID-19 has been associated with a number of cardiovascular complications including dysrhythmias, myocarditis, acute myocardial infarction, and venous thromboembolic events[1]. Several cases of PH related to COVID-19 have now been reported[2-5], however, in the majority of cases, the diagnosis was based on echocardiography data without confirmation via RHC which is the gold standard. Data on hemodynamics in COVID-19 patients on mechanical ventilation has also been published[6].

To our knowledge, this is the first case of PAH confirmed by RHC in non-mechanically ventilated patient following infection with COVID-19.

PAH is defined as a mean pulmonary artery pressure > 20 mmHg measured via RHC with a pulmonary artery wedge pressure < 15 mmHg and pulmonary vascular resistance > 3 units[3,7].

Mechanisms in which new onset PAH develop in the setting of COVID-19 could be multifactorial. Interstitial and alveolar inflammation can lead to extensive pulmonary damage (group 3)[8]. COVID-19 induced endothelial injury[9], microvascular pulmonary thrombosis[10] and hypoxic vasoconstriction[11] could also lead to alterations in pulmonary vasculature (group 4). SARS-COV-2 spike protein has been associated with pulmonary vascular remodeling seen in development of new PAH after COVID-19 infection[12-14].

In addition, positive end-expiratory pressure used in mechanical ventilation increases pulmonary vascular resistance[15], leading to changes in right ventricular function[16,17]. Therefore, the measurement of pulmonary pressures *via* right heart catheterization in mechanically ventilated patients may be falsely elevated[6].

Risk factors for COVID-19 patients developing new onset PAH include a history of cardiac disease[5,18].

Like in our patient, symptoms of COVID-19 induced PAH include persistent dyspnea, cough and fatigue[3]. Our patient continued to experience exertional dyspnea after resolution of her acute COVID-19 illness. This was in spite of resolution of her bilateral lung opacities on imaging and normal PFT and 6MWT studies. Prior to diagnosis with COVID-19, our patient was employed full-time and was very active with no dyspnea.

PAH development after COVID-19 infection can lead to a more severe course of illness[19] and increased mortality[5]. It has been hypothesized that it can be managed with medications such as endothelin receptor antagonists, phosphodiesterase five (PDE-5) inhibitors and prostacyclin, all of which are have been used to treat persons with group 1 PH (PAH)[8,19,20]. However, none of these drugs have been studied in sufficiently powered randomized clinical trials in this specific PAH population[8]. It is also currently unknown whether treatment could reverse the course of this form of PAH.

PAH related to infections is not an uncommon phenomenon. Worldwide, the most common cause of PAH is schistosomiasis[21], and the prevalence of PAH in the human immunodeficiency virus population is 100 to 1000 times greater than in the general population[22-31].

**CONCLUSION**

Development of PAH following infection with COVID-19 is an emerging area that deserves more investigation. Physicians and healthcare providers should have a reasonable level of suspicion for new onset PAH following COVID-19 and subsequently investigate patients presenting with persisting dyspnea following resolution of acute COVID-19 infection.

**REFERENCES**

1 **Long B**, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. *Am J Emerg Med* 2020; **38**: 1504-1507 [PMID: 32317203 DOI: 10.1016/j.ajem.2020.04.048]

2 **van Dongen CM**, Janssen MT, van der Horst RP, van Kraaij DJ, Peeters RH, van den Toorn LM, Mostard RL. Unusually Rapid Development of Pulmonary Hypertension and Right Ventricular Failure after COVID-19 Pneumonia. *Eur J Case Rep Intern Med* 2020; **7**: 001784 [PMID: 32665939 DOI: 10.12890/2020\_001784]

3 **Khan AW**, Ullah I, Khan KS, Tahir MJ, Masyeni S, Harapan H. Pulmonary arterial hypertension post COVID-19: A sequala of SARS-CoV-2 infection? *Respir Med Case Rep* 2021; **33**: 101429 [PMID: 33996435 DOI: 10.1016/j.rmcr.2021.101429]

4 **Tudoran C**, Tudoran M, Lazureanu VE, Marinescu AR, Pop GN, Pescariu AS, Enache A, Cut TG. Evidence of Pulmonary Hypertension after SARS-CoV-2 Infection in Subjects without Previous Significant Cardiovascular Pathology. *J Clin Med* 2021; **10** [PMID: 33430492 DOI: 10.3390/jcm10020199]

5 **Pagnesi M**, Baldetti L, Beneduce A, Calvo F, Gramegna M, Pazzanese V, Ingallina G, Napolano A, Finazzi R, Ruggeri A, Ajello S, Melisurgo G, Camici PG, Scarpellini P, Tresoldi M, Landoni G, Ciceri F, Scandroglio AM, Agricola E, Cappelletti AM. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. *Heart* 2020; **106**: 1324-1331 [PMID: 32675217 DOI: 10.1136/heartjnl-2020-317355]

6 **Caravita S**, Baratto C, Di Marco F, Calabrese A, Balestrieri G, Russo F, Faini A, Soranna D, Perego GB, Badano LP, Grazioli L, Lorini FL, Parati G, Senni M. Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization. *Eur J Heart Fail* 2020; **22**: 2228-2237 [PMID: 33200458 DOI: 10.1002/ejhf.2058]

7 **Simonneau G**, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* 2019; **53** [PMID: 30545968 DOI: 10.1183/13993003.01913-2018]

8 **Eroume À Egom E**, Shiwani HA, Nouthe B. From acute SARS-CoV-2 infection to pulmonary hypertension. *Front Physiol* 2022; **13**: 1023758 [PMID: 36601347 DOI: 10.3389/fphys.2022.1023758]

9 **Wang X**, Tu Y, Huang B, Li Y, Li Y, Zhang S, Lin Y, Huang L, Zhang W, Luo H. Pulmonary vascular endothelial injury and acute pulmonary hypertension caused by COVID-19: the fundamental cause of refractory hypoxemia? *Cardiovasc Diagn Ther* 2020; **10**: 892-897 [PMID: 32968645 DOI: 10.21037/cdt-20-429]

10 **Ciceri F**, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, Peccatori J, D'Angelo A, De Cobelli F, Rovere-Querini P, Tresoldi M, Dagna L, Zangrillo A. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. *Crit Care Resusc* 2020; **22**: 95-97 [PMID: 32294809 DOI: 10.51893/2020.2.pov2]

11 **Sylvester JT**, Shimoda LA, Aaronson PI, Ward JP. Hypoxic pulmonary vasoconstriction. *Physiol Rev* 2012; **92**: 367-520 [PMID: 22298659 DOI: 10.1152/physrev.00041.2010]

12 **Suzuki YJ**, Nikolaienko SI, Dibrova VA, Dibrova YV, Vasylyk VM, Novikov MY, Shults NV, Gychka SG. SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells. *Vascul Pharmacol* 2021; **137**: 106823 [PMID: 33232769 DOI: 10.1016/j.vph.2020.106823]

13 **Mamzer A**, Waligora M, Kopec G, Ptaszynska-Kopczynska K, Kurzyna M, Darocha S, Florczyk M, Mroczek E, Mularek-Kubzdela T, Smukowska-Gorynia A, Wrotynski M, Chrzanowski L, Dzikowska-Diduch O, Perzanowska-Brzeszkiewicz K, Pruszczyk P, Skoczylas I, Lewicka E, Blaszczak P, Karasek D, Kusmierczyk-Droszcz B, Mizia-Stec K, Kaminski K, Jachec W, Peregud-Pogorzelska M, Doboszynska A, Gasior Z, Tomaszewski M, Pawlak A, Zablocka W, Ryczek R, Widejko-Pietkiewicz K, Kasprzak JD. Impact of the COVID-19 Pandemic on Pulmonary Hypertension Patients: Insights from the BNP-PL National Database. *Int J Environ Res Public Health* 2022; **19** [PMID: 35886278 DOI: 10.3390/ijerph19148423]

14 **Thenappan T**, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. *BMJ* 2018; **360**: j5492 [PMID: 29540357 DOI: 10.1136/bmj.j5492]

15 **Corp A**, Thomas C, Adlam M. The cardiovascular effects of positive pressure ventilation. *BJA Educ* 2021; **21**: 202-209 [PMID: 34026273 DOI: 10.1016/j.bjae.2021.01.002]

16 **Jardin F**, Delorme G, Hardy A, Auvert B, Beauchet A, Bourdarias JP. Reevaluation of hemodynamic consequences of positive pressure ventilation: emphasis on cyclic right ventricular afterloading by mechanical lung inflation. *Anesthesiology* 1990; **72**: 966-970 [PMID: 2190501 DOI: 10.1097/00000542-199006000-00003]

17 **Vieillard-Baron A**, Jardin F. Why protect the right ventricle in patients with acute respiratory distress syndrome? *Curr Opin Crit Care* 2003; **9**: 15-21 [PMID: 12548024 DOI: 10.1097/00075198-200302000-00004]

18 **Wolters AEP**, Wolters AJP, van Kraaij TDA, Kietselaer BLJH. Echocardiographic estimation of pulmonary hypertension in COVID-19 patients. *Neth Heart J* 2022; **30**: 510-518 [PMID: 35771380 DOI: 10.1007/s12471-022-01702-x]

19 **Castiglione L**, Droppa M. Pulmonary Hypertension and COVID-19. *Hamostaseologie* 2022; **42**: 230-238 [PMID: 34933375 DOI: 10.1055/a-1661-0240]

20 **Raval A,** Edwards N, Kant R, Verma V. COVID-19 as a primary cause of pulmonary arterial hypertension. *Chest* 2021; **160:** A2198 [DOI: 10.1016/j.chest.2021.07.1939]

21 **Fernandes CJ**, Jardim CV, Hovnanian A, Hoette S, Morinaga LK, Souza R. Schistosomiasis and pulmonary hypertension. *Expert Rev Respir Med* 2011; **5**: 675-681 [PMID: 21955237 DOI: 10.1586/ers.11.58]

22 **Mehta NJ**, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. *Chest* 2000; **118**: 1133-1141 [PMID: 11035689 DOI: 10.1378/chest.118.4.1133]

23 **Humbert M**, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Simonneau G. Pulmonary arterial hypertension in France: results from a national registry. *Am J Respir Crit Care Med* 2006; **173**: 1023-1030 [PMID: 16456139 DOI: 10.1164/rccm.200510-1668OC]

24 **Speich R**, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. *Chest* 1991; **100**: 1268-1271 [PMID: 1935280 DOI: 10.1378/chest.100.5.1268]

25 **Barbarinia G**, Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. *AIDS* 2003; **17 Suppl 1**: S46-S50 [PMID: 12870530]

26 **Sitbon O**, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D, Gressin V, Clerson P, Sereni D, Simonneau G. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. *Am J Respir Crit Care Med* 2008; **177**: 108-113 [PMID: 17932378 DOI: 10.1164/rccm.200704-541OC]

27 **Mesa RA**, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. *Mayo Clin Proc* 1998; **73**: 37-45 [PMID: 9443676 DOI: 10.1016/s0025-6196(11)63616-1]

28 **Himelman RB**, Dohrmann M, Goodman P, Schiller NB, Starksen NF, Warnock M, Cheitlin MD. Severe pulmonary hypertension and cor pulmonale in the acquired immunodeficiency syndrome. *Am J Cardiol* 1989; **64**: 1396-1399 [PMID: 2531539 DOI: 10.1016/0002-9149(89)90594-8]

29 **Isasti G**, Moreno T, Pérez I, Cabrera F, Palacios R, Santos J. High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients. *AIDS Res Hum Retroviruses* 2013; **29**: 231-234 [PMID: 22849654 DOI: 10.1089/AID.2012.0166]

30 **Opravil M**, Pechère M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, Hirschel B, Lüthy R. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. *Am J Respir Crit Care Med* 1997; **155**: 990-995 [PMID: 9117037 DOI: 10.1164/ajrccm.155.3.9117037]

31 **Pellicelli AM**, Barbaro G, Palmieri F, Girardi E, D'Ambrosio C, Rianda A, Barbarini G, Frigiotti D, Borgia MC, Petrosillo N. Primary pulmonary hypertension in HIV patients: a systematic review. *Angiology* 2001; **52**: 31-41 [PMID: 11205929 DOI: 10.1177/000331970105200105]

**Footnotes**

**Informed consent statement:** Patient in this case report provided informed written consent.

**Conflict-of-interest statement:** All the authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 31, 2022

**First decision:** January 20, 2023

**Article in press:** May 8, 2023

**Specialty type:** Respiratory system

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Juneja D, India; Su C, China; Velikova TV, Bulgaria **S-Editor:** Liu JH **L-Editor:** A **P-Editor:** Zhao S

**Table 1 Right heart catheterization data obtained in patient post-coronavirus disease 2019**

|  |  |  |
| --- | --- | --- |
|  | **Measured values** | **Normal values** |
| Right atrial pressure | 5 mmHg  | 0-7 mmHg |
| Right ventricular pressure, systolic/diastolic | 40/2 mmHg | 45/2 mmHg |
| Pulmonary artery pressure, systolic/diastolic (mean) | 37/14 (25) mmHg | 25/12 (16) mmHg |
| Pulmonary capillary wedge pressure | 8 mmHg | 6-12 mmHg |
| Pulmonary vascular resistance | 5 Wood Units (418 Dynes.sec.cm-5) | < 3 Wood Units  |
|  |  | (< 250 Dynes.sec.cm-5) |
| Transpulmonary gradient | 17 mmHg | < 12 mmHg |
| Fick cardiac output | 3.25 L/min | 4.8–7.3 L/min |
| Cardiac index | 1.79 L/min/m2 | 2.8–4.2 L/min/m2 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**